If there's one word I (and probably most people) have come to fear more than all others, it's "failure." We've been conditioned since grade school that failure is shameful and punishment worthy. Maybe even something we should tuck away in our knapsack, sneak past Mom and Dad, tear into little pieces, and hide under the carpet.
If there's one word I (and probably most people) have come to fear more than all others, it's "failure." We've been conditioned since grade school that failure is shameful and punishment worthy. Maybe even something we should tuck away in our knapsack, sneak past Mom and Dad, tear into little pieces, and hide under the carpet.
Kaylynn Chiarello-Ebner
As adults, we're often given to similar behavior. If an experiment doesn't work as well as expected, it's unlikely we'll sprint to our computers, type up the results, and send it out to be published. Call it pride or competitiveness if you will, but it's much more comfortable to share information about enhancing a drug's properties, accelerating validation time, or cutting production costs.
Of course, positive results can provide industry invaluable information, but failed experiments can be healthy, too—by showing conclusively a given technique isn't productive in some applications, for example.Yes it's cliché, but we can only learn from our mistakes if we acknowledge them. Negative results, as frustrating as they may be, should be shared with others and added to our bank of literature. I will go so far as to say that if we don't publish studies with failed results, our literature thereby is unbalanced and biased.
Now, that's not to say that absolutely all negative results are fruitful. Like all good published research, data must be derived from logical, well-designed, methods that are executed by conscientious, well-trained researchers. Sufficient evidence must be given to support any claims. If they meet the requirements, negative studies merit as much thought and discussion as the positive.
Kaylynn Chiarello-Ebner is the managing editor of Pharmaceutical Technology, kchiarello@advanstar.com
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.